ANAM-17-21
10 Nov 2020
Trial Summary
Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl.
Acronym:
ANAM-17-21
ACTRN/NCT /ethics:
NCT03743064
Scientific title:
A phase III, randomised, double-blind, placebo-controlled, mutli-centre study to evaluate the efficacy and safety of anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC.
Sponsor / Cooperative group:
Helsinn Healthcare SA
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | NSCLC |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2018-12-18 |
| Anticipated End Date | 2023-01-31 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Vineet Kwatra |
| Recruitment Status | Recruiting |